阿立哌唑与利培酮治疗精神分裂症对照研究.DOCVIP

临床医学论文-阿立哌唑与利培酮治疗精神分裂症对照研究 【关键词】? 精神分裂症；阿立哌唑；利培酮；简明精神病评定量表 　　【摘要】 目的? 探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。 方法? 将68例精神分裂症患者随机分为研究组36例，对照组32例，分别给予阿立哌唑及利培酮治疗，疗程8 w。采用简明精神病评定量表、阴性症状量表、大体评定量表评定临床疗效，副反应量表评定不良反应。 结果? 研究组总有效率84%，对照组92%，两组总体疗效相当（P＞0.05）。两组各时点简明精神病量表、阴性症状量表评分均较治疗前显著下降（P＜0.05或0.01）。研究组治疗第1 w、2 w、4 w末思维障碍、激活性、敌对猜疑、注意障碍等因子分较对照组下降显著（P＜0.05或0.01）。研究组用药初期主要不良反应为嗜睡，头晕、头痛、胃肠道反应，1 w后可自行缓解或消失。 结论? 阿立哌唑治疗精神分裂症疗效与利培酮相当，但起效更快。 　　【关键词】 精神分裂症；阿立哌唑；利培酮；简明精神病评定量表 　　Control study of aripiprazole and risperidone in the treatment of schizophrenia 　　【Abstract】 Objective? To explore the clinical efficacy and safety of? aripiprazole and risperidone in the treatment of schizophrenia.Methods? 68 schizophrenics were divided into research group(n=36) taking aripiprazole and control group(n=32) taking risperidone for 8 weeks. Curative effects were assessed with the BPRS,SANS and GAS, and adverse effects with the TESS.? Results? Total effective rates were 84% of the research group and 92% of the control group respectively, global efficacies of the 2 groups were equivalent(P＞0.05). Timepoint scores of the BPRS and SANS for both groups decreased significantly compared with pretreatment(P＜0.05 or 0.01). In the research group, factors’ score such as thinking disturbance, activity, hostilitysuspicion and disturbance of attention decreased notably at the ends of the 1st, 2nd and 4th week compared with the control group(P＜0.05 or 0.01). Main adverse effects in the research group were drowsiness, dizzy, headache and gastrointestinal reactions in the initial stage of medication which relieved or disappeared voluntarily in one week. Conclusion? Aripiprazolein has equivalent efficacy to risperidone in the treatment of schizophrenia and takes effect faster.?　　【Keywords】 Schizophrenia；aripiprazole；risperidone; the BPRS ??? 阿立哌唑（Aripiprazole）为第三代抗精神病药，与传统抗精神病药物的作用不同,主要通过对D2和5羟色胺1A（5HT1A）受体的部分激动作用以及通过对5HT2A受体的拮抗作用而共同起效，是多巴胺（DA）和5HT系统稳定剂。目前已在美国《专家用药指南》中被推荐为与利培酮（Risperidone）相并列的治疗首发或复发性精神分裂症首选药物［1］。为了探讨阿立哌唑治疗精神分